FDA label 8d41c186-e6eb-75c6-e053-2995a90a8415

WARNINGS Deterioration in Renal Function Bisphosphonates, including pamidronate disodium, have been associated with renal toxicity manifested as deterioration of renal function and potential renal failure. DUE TO THE RISK OF CLINICALLY SIGNIFICANT DETERIORATION IN RENAL FUNCTION, WHICH MAY PROGRESS TO RENAL FAILURE, SINGLE DOSES OF PAMIDRONATE DISODIUM SHOULD NOT EXCEED 90 MG (see DOSAGE AND ADMINISTRATION for appropriate infusion durations). Renal deterioration, progression to renal failure, and dialysis have been reported in patients after the initial or a single dose of pamidronate disodium. Focal segmental glomerulosclerosis (including the collapsing variant) with or without nephrotic syndrome, which may lead to renal failure, has been reported in pamidronate disodium-treated patients, particularly in the setting of multiple myeloma and breast cancer. Some of these patients had gradual improvement in renal status after pamidronate disodium was discontinued. Patients who receive pamidronate disodium should have serum creatinine assessed prior to each treatment. Patients treated with pamidronate disodium for bone metastases should have the dose withheld if renal function has deteriorated (see DOSAGE AND ADMINISTRATION ). PREGNANCY: PAMIDRONATE DISODIUM SHOULD NOT BE USED DURING PREGNANCY. Pamidronate disodium may cause fetal harm when administered to a pregnant women (see PRECAUTIONS, Pregnancy Category D ). There are no studies in pregnant women using pamidronate disodium. If the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant. Studies conducted in young rats have reported the disruption of dental dentine formation following single- and multi-dose administration of bisphosphonates. The clinical significance of these findings is unknown.

Deterioration in Renal Function Bisphosphonates, including pamidronate disodium, have been associated with renal toxicity manifested as deterioration of renal function and potential renal failure. DUE TO THE RISK OF CLINICALLY SIGNIFICANT DETERIORATION IN RENAL FUNCTION, WHICH MAY PROGRESS TO RENAL FAILURE, SINGLE DOSES OF PAMIDRONATE DISODIUM SHOULD NOT EXCEED 90 MG (see DOSAGE AND ADMINISTRATION for appropriate infusion durations). Renal deterioration, progression to renal failure, and dialysis have been reported in patients after the initial or a single dose of pamidronate disodium. Focal segmental glomerulosclerosis (including the collapsing variant) with or without nephrotic syndrome, which may lead to renal failure, has been reported in pamidronate disodium-treated patients, particularly in the setting of multiple myeloma and breast cancer. Some of these patients had gradual improvement in renal status after pamidronate disodium was discontinued. Patients who receive pamidronate disodium should have serum creatinine assessed prior to each treatment. Patients treated with pamidronate disodium for bone metastases should have the dose withheld if renal function has deteriorated (see DOSAGE AND ADMINISTRATION ).

PREGNANCY: PAMIDRONATE DISODIUM SHOULD NOT BE USED DURING PREGNANCY. Pamidronate disodium may cause fetal harm when administered to a pregnant women (see PRECAUTIONS, Pregnancy Category D ). There are no studies in pregnant women using pamidronate disodium. If the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant. Studies conducted in young rats have reported the disruption of dental dentine formation following single- and multi-dose administration of bisphosphonates. The clinical significance of these findings is unknown.

ADVERSE REACTIONS Clinical Studies Hypercalcemia of Malignancy Transient mild elevation of temperature by at least 1°C was noted 24 to 48 hours after administration of pamidronate disodium in 34% of patients in clinical trials. In the saline trial, 18% of patients had a temperature elevation of at least 1°C 24 to 48 hours after treatment. Drug-related local soft-tissue symptoms (redness, swelling or induration and pain on palpation) at the site of catheter insertion were most common in patients treated with 90 mg of pamidronate disodium. Symptomatic treatment resulted in rapid resolution in all patients. Rare cases of uveitis, iritis, scleritis, and episcleritis have been reported, including one case of scleritis, and one case of uveitis upon separate rechallenges. Five of 231 patients (2%) who received pamidronate disodium during the four U.S. controlled hypercalcemia clinical studies were reported to have had seizures, two of whom had preexisting seizure disorders. None of the seizures were considered to be drug-related by the investigators. However, a possible relationship between the drug and the occurrence of seizures cannot be ruled out. It should be noted that in the saline arm one patient (4%) had a seizure. There are no controlled clinical trials comparing the efficacy and safety of 90 mg pamidronate disodium over 24 hours to 2 hours in patients with hypercalcemia of malignancy. However, a comparison of data from separate clinical trials suggests that the overall safety profile in patients who received 90 mg pamidronate disodium over 24 hours is similar to those who received 90 mg pamidronate disodium over 2 hours. The only notable differences observed were an increase in the proportion of patients in the pamidronate disodium 24 hours group who experienced fluid overload and electrolyte/mineral abnormalities. At least 15% of patients treated with pamidronate disodium for hypercalcemia of malignancy also experienced the following adverse events during a clinical trial: General : Fluid overload, generalized pain Cardiovascular : Hypertension Gastrointestinal : Abdominal pain, anorexia, constipation, nausea, vomiting Genitourinary : Urinary tract infection Musculoskeletal : Bone pain Laboratory Abnormality : Anemia, hypokalemia, hypomagnesemia, hypophosphatemia Many of these adverse experiences may have been related to the underlying disease state. Table 6 lists the adverse experiences considered to be treatment-related during comparative, controlled U.S. trials. Table 6 Treatment-Related Adverse Experiences Reported in Three U.S. Controlled Clinical Trials Percent of Patients Pamidronate Disodium Etidronate Disodium Saline 60 mg over 4 hr 60 mg over 24 hr 90 mg over 24 hr 7.5 mg/kg x 3 days n=23 n=73 n=17 n=35 n=23 General Edema 0 1 0 0 0 Fatigue 0 0 12 0 0 Fever 26 19 18 9 0 Fluid overload 0 0 0 6 0 Infusion-site reaction 0 4 18 0 0 Moniliasis 0 0 6 0 0 Rigors 0 0 0 0 4 Gastrointestinal Abdominal pain 0 1 0 0 0 Anorexia 4 1 12 0 0 Constipation 4 0 6 3 0 Diarrhea 0 1 0 0 0 Dyspepsia 4 0 0 0 0 Gastrointestinal hemorrhage 0 0 6 0 0 Nausea 4 0 18 6 0 Stomatitis 0 1 0 3 0 Vomiting 4 0 0 0 0 Respiratory Dyspnea 0 0 0 3 0 Rales 0 0 6 0 0 Rhinitis 0 0 6 0 0 Upper respiratory infection 0 3 0 0 0 CNS Anxiety 0 0 0 0 4 Convulsions 0 0 0 3 0 Insomnia 0 1 0 0 0 Nervousness 0 0 0 0 4 Psychosis 4 0 0 0 0 Somnolence 0 1 6 0 0 Taste perversion 0 0 0 3 0 Cardiovascular Atrial fibrillation 0 0 6 0 4 Atrial flutter 0 1 0 0 0 Cardiac failure 0 1 0 0 0 Hypertension 0 0 6 0 4 Syncope 0 0 6 0 0 Tachycardia 0 0 6 0 4 Endocrine Hypothyroidism 0 0 6 0 0 Hemic and Lymphatic Anemia 0 0 6 0 0 Leukopenia 4 0 0 0 0 Neutropenia 0 1 0 0 0 Thrombocytopenia 0 1 0 0 0 Musculoskeletal Myalgia 0 1 0 0 0 Urogenital Uremia 4 0 0 0 0 Laboratory Abnormalities Hypocalcemia 0 1 12 0 0 Hypokalemia 4 4 18 0 0 Hypomagnesemia 4 10 12 3 4 Hypophosphatemia 0 9 18 3 0 Abnormal liver function 0 0 0 3 0 Paget’s Disease Transient mild elevation of temperature >1°C above pretreatment baseline was noted within 48 hours after completion of treatment in 21% of the patients treated with 90 mg of pamidronate disodium in clinical trials. Drug-related musculoskeletal pain and nervous system symptoms (dizziness, headache, paresthesia, increased sweating) were more common in patients with Paget’s disease treated with 90 mg of pamidronate disodium than in patients with hypercalcemia of malignancy treated with the same dose. Adverse experiences considered to be related to trial drug, which occurred in at least 5% of patients with Paget’s disease treated with 90 mg of pamidronate disodium in two U.S. clinical trials, were fever, nausea, back pain, and bone pain. At least 10% of all pamidronate disodium-treated patients with Paget’s disease also experienced the following adverse experiences during clinical trials: Cardiovascular : Hypertension Musculoskeletal : Arthrosis, bone pain Nervous system : Headache Most of these adverse experiences may have been related to the underlying disease state. Osteolytic Bone Metastases of Breast Cancer and Osteolytic Lesions of Multiple Myeloma The most commonly reported (>15%) adverse experiences occurred with similar frequencies in the pamidronate disodium- and placebo-treatment groups, and most of these adverse experiences may have been related to the underlying disease state or cancer therapy (see Table 7 below). Table 7 Commonly Reported Adverse Experiences in Three U.S. Controlled Clinical Trials Pamidronate Disodium 90 mg over 4 hours N=205 % Placebo N=187 % Pamidronate Disodium 90 mg over 2 hours N=367 % Placebo N=386 % All Pamidronate Disodium 90 mg N=572 % Placebo N=573 % General Asthenia 16.1 17.1 25.6 19.2 22.2 18.5 Fatigue 31.7 28.3 40.3 28.8 37.2 29 Fever 38.5 38 38.1 32.1 38.5 34 Metastases 1 3 31.3 24.4 20.5 17.5 Pain 13.2 11.8 15 18.1 14.3 16.1 Digestive System Anorexia 17.1 17.1 31.1 24.9 26 22.3 Constipation 28.3 31.7 36 38.6 33.2 35.1 Diarrhea 26.8 26.8 29.4 30.6 28.5 29.7 Dyspepsia 17.6 13.4 18.3 15 22.6 17.5 Nausea 35.6 37.4 63.5 59.1 53.5 51.8 Pain Abdominal 19.5 16 24.3 18.1 22.6 17.5 Vomiting 16.6 19.8 46.3 39.1 35.7 32.8 Hemic and Lymphatic Anemia 47.8 41.7 39.5 36.8 42.5 38.4 Granulocytopenia 20.5 15.5 19.3 20.5 19.8 18.8 Thrombocytopenia 16.6 17.1 12.5 14.1 14 15 Musculoskeletal System Arthralgias 10.7 7 15.3 12.7 13.6 10.8 Myalgia 25.4 15 26.4 22.5 26 20.1 Skeletal pain 61 71.7 70 75.4 66.8 74 CNS Anxiety 7.8 9.1 18 16.8 14.3 14.3 Headache 24.4 19.8 27.2 23.6 26.2 22.3 Insomnia 17.1 17.2 25.1 19.4 22.2 19.1 Respiratory System Coughing 26.3 22.5 25.3 19.7 25.7 20.6 Dyspnea 22 21.4 35.1 24.4 30.4 23.4 Pleural Effusion 2.9 4.3 15 9.1 10.7 7.5 Sinusitis 14.6 16.6 16.1 10.4 15.6 12 Upper Respiratory Tract Infection 32.2 28.3 19.6 20.2 24.1 22.9 Urogenital System Urinary Tract Infection 15.6 9.1 20.2 17.6 18.5 15.6 Of the toxicities commonly associated with chemotherapy, the frequency of vomiting, anorexia, and anemia were slightly more common in the pamidronate disodium patients whereas stomatitis and alopecia occurred at a frequency similar to that in placebo patients. In the breast cancer trials, mild elevations of serum creatinine occurred in 18.5% of pamidronate disodium patients and 12.3% of placebo patients. Mineral and electrolyte disturbances, including hypocalcemia, were reported rarely and in similar percentages of pamidronate disodium-treated patients compared with those in the placebo group. The reported frequencies of hypocalcemia, hypokalemia, hypophosphatemia, and hypomagnesemia for pamidronate disodium-treated patients were 3.3%, 10.5%, 1.7%, and 4.4%, respectively, and for placebo-treated patients were 1.2%, 12%, 1.7%, and 4.5%, respectively. In previous hypercalcemia of malignancy trials, patients treated with pamidronate disodium (60 or 90 mg over 24 hours) developed electrolyte abnormalities more frequently (see ADVERSE REACTIONS , Hypercalcemia of Malignancy ). Arthralgias and myalgias were reported slightly more frequently in the pamidronate disodium group than in the placebo group (13.6% and 26% vs 10.8% and 20.1%, respectively). In multiple myeloma patients, there were five pamidronate disodium-related serious and unexpected adverse experiences. Four of these were reported during the 12-month extension of the multiple myeloma trial. Three of the reports were of worsening renal function developing in patients with progressive multiple myeloma or multiple myeloma-associated amyloidosis. The fourth report was the adult respiratory distress syndrome developing in a patient recovering from pneumonia and acute gangrenous cholecystitis. One pamidronate disodium-treated patient experienced an allergic reaction characterized by swollen and itchy eyes, runny nose, and scratchy throat within 24 hours after the sixth infusion. In the breast cancer trials, there were four pamidronate disodium-related adverse experiences, all moderate in severity, that caused a patient to discontinue participation in the trial. One was due to interstitial pneumonitis, another to malaise and dyspnea. One pamidronate disodium patient discontinued the trial due to a symptomatic hypocalcemia. Another pamidronate disodium patient discontinued therapy due to severe bone pain after each infusion, which the investigator felt was trial-drug-related. Renal Toxicity In a study of the safety and efficacy of pamidronate disodium injection 90 mg (2 hour infusion) versus zoledronic acid injection 4 mg (15 minute infusion) in bone metastases patients with multiple myeloma or breast cancer, renal deterioration was defined as an increase in serum creatinine of 0.5 mg/dL for patients with normal baseline creatinine (<1.4 mg/dL) or an increase of 1 mg/dL for patients with an abnormal baseline creatinine (≥ 1.4 mg/dL). The following are data on the incidence of renal deterioration in patients in this trial. See Table 8 below. Table 8 Incidence of Renal Function Deterioration in Multiple Myeloma and Breast Cancer Patients with Normal and Abnormal Serum Creatinine at Baseline* Patient Population/ Baseline Creatinine Pamidronate Disodium Injection 90 mg/2 hours Zoledronic Acid Injection 4 mg/15 minutes n/N (%) n/N (%) Normal 20/246 (8.1%) 23/246 (9.3%) Abnormal 2/22 (9.1%) 1/26 (3.8%) Total 22/268 (8.2%) 24/272 (8.8%) * Patients were randomized following the 15 minute infusion amendment for the zoledronic acid injection arm. Post-Marketing Experience The following adverse reactions have been reported in post-marketing use: General : reactivation of Herpes simplex and Herpes zoster, influenza-like symptoms; CNS : confusion and visual hallucinations, sometimes in the presence of electrolyte imbalance; Skin : rash, pruritus; Special senses : conjunctivitis, orbital inflammation; Renal : focal segmental glomerulosclerosis including the collapsing variant, nephrotic syndrome; Laboratory abnormalities : hyperkalemia, hypernatremia, hematuria. Rare instances of allergic manifestations have been reported, including hypotension, dyspnea, or angioedema, and, very rarely, anaphylactic shock. Pamidronate disodium is contraindicated in patients with clinically significant hypersensitivity to pamidronate disodium or other bisphosphonates (see CONTRAINDICATIONS ). Cases of osteonecrosis (primarily involving the jaw) have been reported predominantly in cancer patients treated with intravenous bisphosphonates, including pamidronate disodium. Many of these patients were also receiving chemotherapy and corticosteroids which may be risk factors for ONJ. Data suggest a greater frequency of reports of ONJ in certain cancers, such as advanced breast cancer and multiple myeloma. The majority of the reported cases are in cancer patients following invasive dental procedures, such as tooth extraction. It is therefore prudent to avoid invasive dental procedures as recovery may be prolonged (see PRECAUTIONS ).

Clinical Studies Hypercalcemia of Malignancy Transient mild elevation of temperature by at least 1°C was noted 24 to 48 hours after administration of pamidronate disodium in 34% of patients in clinical trials. In the saline trial, 18% of patients had a temperature elevation of at least 1°C 24 to 48 hours after treatment. Drug-related local soft-tissue symptoms (redness, swelling or induration and pain on palpation) at the site of catheter insertion were most common in patients treated with 90 mg of pamidronate disodium. Symptomatic treatment resulted in rapid resolution in all patients. Rare cases of uveitis, iritis, scleritis, and episcleritis have been reported, including one case of scleritis, and one case of uveitis upon separate rechallenges. Five of 231 patients (2%) who received pamidronate disodium during the four U.S. controlled hypercalcemia clinical studies were reported to have had seizures, two of whom had preexisting seizure disorders. None of the seizures were considered to be drug-related by the investigators. However, a possible relationship between the drug and the occurrence of seizures cannot be ruled out. It should be noted that in the saline arm one patient (4%) had a seizure. There are no controlled clinical trials comparing the efficacy and safety of 90 mg pamidronate disodium over 24 hours to 2 hours in patients with hypercalcemia of malignancy. However, a comparison of data from separate clinical trials suggests that the overall safety profile in patients who received 90 mg pamidronate disodium over 24 hours is similar to those who received 90 mg pamidronate disodium over 2 hours. The only notable differences observed were an increase in the proportion of patients in the pamidronate disodium 24 hours group who experienced fluid overload and electrolyte/mineral abnormalities. At least 15% of patients treated with pamidronate disodium for hypercalcemia of malignancy also experienced the following adverse events during a clinical trial: General : Fluid overload, generalized pain Cardiovascular : Hypertension Gastrointestinal : Abdominal pain, anorexia, constipation, nausea, vomiting Genitourinary : Urinary tract infection Musculoskeletal : Bone pain Laboratory Abnormality : Anemia, hypokalemia, hypomagnesemia, hypophosphatemia Many of these adverse experiences may have been related to the underlying disease state. Table 6 lists the adverse experiences considered to be treatment-related during comparative, controlled U.S. trials. Table 6 Treatment-Related Adverse Experiences Reported in Three U.S. Controlled Clinical Trials Percent of Patients Pamidronate Disodium Etidronate Disodium Saline 60 mg over 4 hr 60 mg over 24 hr 90 mg over 24 hr 7.5 mg/kg x 3 days n=23 n=73 n=17 n=35 n=23 General Edema 0 1 0 0 0 Fatigue 0 0 12 0 0 Fever 26 19 18 9 0 Fluid overload 0 0 0 6 0 Infusion-site reaction 0 4 18 0 0 Moniliasis 0 0 6 0 0 Rigors 0 0 0 0 4 Gastrointestinal Abdominal pain 0 1 0 0 0 Anorexia 4 1 12 0 0 Constipation 4 0 6 3 0 Diarrhea 0 1 0 0 0 Dyspepsia 4 0 0 0 0 Gastrointestinal hemorrhage 0 0 6 0 0 Nausea 4 0 18 6 0 Stomatitis 0 1 0 3 0 Vomiting 4 0 0 0 0 Respiratory Dyspnea 0 0 0 3 0 Rales 0 0 6 0 0 Rhinitis 0 0 6 0 0 Upper respiratory infection 0 3 0 0 0 CNS Anxiety 0 0 0 0 4 Convulsions 0 0 0 3 0 Insomnia 0 1 0 0 0 Nervousness 0 0 0 0 4 Psychosis 4 0 0 0 0 Somnolence 0 1 6 0 0 Taste perversion 0 0 0 3 0 Cardiovascular Atrial fibrillation 0 0 6 0 4 Atrial flutter 0 1 0 0 0 Cardiac failure 0 1 0 0 0 Hypertension 0 0 6 0 4 Syncope 0 0 6 0 0 Tachycardia 0 0 6 0 4 Endocrine Hypothyroidism 0 0 6 0 0 Hemic and Lymphatic Anemia 0 0 6 0 0 Leukopenia 4 0 0 0 0 Neutropenia 0 1 0 0 0 Thrombocytopenia 0 1 0 0 0 Musculoskeletal Myalgia 0 1 0 0 0 Urogenital Uremia 4 0 0 0 0 Laboratory Abnormalities Hypocalcemia 0 1 12 0 0 Hypokalemia 4 4 18 0 0 Hypomagnesemia 4 10 12 3 4 Hypophosphatemia 0 9 18 3 0 Abnormal liver function 0 0 0 3 0 Paget’s Disease Transient mild elevation of temperature >1°C above pretreatment baseline was noted within 48 hours after completion of treatment in 21% of the patients treated with 90 mg of pamidronate disodium in clinical trials. Drug-related musculoskeletal pain and nervous system symptoms (dizziness, headache, paresthesia, increased sweating) were more common in patients with Paget’s disease treated with 90 mg of pamidronate disodium than in patients with hypercalcemia of malignancy treated with the same dose. Adverse experiences considered to be related to trial drug, which occurred in at least 5% of patients with Paget’s disease treated with 90 mg of pamidronate disodium in two U.S. clinical trials, were fever, nausea, back pain, and bone pain. At least 10% of all pamidronate disodium-treated patients with Paget’s disease also experienced the following adverse experiences during clinical trials: Cardiovascular : Hypertension Musculoskeletal : Arthrosis, bone pain Nervous system : Headache Most of these adverse experiences may have been related to the underlying disease state. Osteolytic Bone Metastases of Breast Cancer and Osteolytic Lesions of Multiple Myeloma The most commonly reported (>15%) adverse experiences occurred with similar frequencies in the pamidronate disodium- and placebo-treatment groups, and most of these adverse experiences may have been related to the underlying disease state or cancer therapy (see Table 7 below). Table 7 Commonly Reported Adverse Experiences in Three U.S. Controlled Clinical Trials Pamidronate Disodium 90 mg over 4 hours N=205 % Placebo N=187 % Pamidronate Disodium 90 mg over 2 hours N=367 % Placebo N=386 % All Pamidronate Disodium 90 mg N=572 % Placebo N=573 % General Asthenia 16.1 17.1 25.6 19.2 22.2 18.5 Fatigue 31.7 28.3 40.3 28.8 37.2 29 Fever 38.5 38 38.1 32.1 38.5 34 Metastases 1 3 31.3 24.4 20.5 17.5 Pain 13.2 11.8 15 18.1 14.3 16.1 Digestive System Anorexia 17.1 17.1 31.1 24.9 26 22.3 Constipation 28.3 31.7 36 38.6 33.2 35.1 Diarrhea 26.8 26.8 29.4 30.6 28.5 29.7 Dyspepsia 17.6 13.4 18.3 15 22.6 17.5 Nausea 35.6 37.4 63.5 59.1 53.5 51.8 Pain Abdominal 19.5 16 24.3 18.1 22.6 17.5 Vomiting 16.6 19.8 46.3 39.1 35.7 32.8 Hemic and Lymphatic Anemia 47.8 41.7 39.5 36.8 42.5 38.4 Granulocytopenia 20.5 15.5 19.3 20.5 19.8 18.8 Thrombocytopenia 16.6 17.1 12.5 14.1 14 15 Musculoskeletal System Arthralgias 10.7 7 15.3 12.7 13.6 10.8 Myalgia 25.4 15 26.4 22.5 26 20.1 Skeletal pain 61 71.7 70 75.4 66.8 74 CNS Anxiety 7.8 9.1 18 16.8 14.3 14.3 Headache 24.4 19.8 27.2 23.6 26.2 22.3 Insomnia 17.1 17.2 25.1 19.4 22.2 19.1 Respiratory System Coughing 26.3 22.5 25.3 19.7 25.7 20.6 Dyspnea 22 21.4 35.1 24.4 30.4 23.4 Pleural Effusion 2.9 4.3 15 9.1 10.7 7.5 Sinusitis 14.6 16.6 16.1 10.4 15.6 12 Upper Respiratory Tract Infection 32.2 28.3 19.6 20.2 24.1 22.9 Urogenital System Urinary Tract Infection 15.6 9.1 20.2 17.6 18.5 15.6 Of the toxicities commonly associated with chemotherapy, the frequency of vomiting, anorexia, and anemia were slightly more common in the pamidronate disodium patients whereas stomatitis and alopecia occurred at a frequency similar to that in placebo patients. In the breast cancer trials, mild elevations of serum creatinine occurred in 18.5% of pamidronate disodium patients and 12.3% of placebo patients. Mineral and electrolyte disturbances, including hypocalcemia, were reported rarely and in similar percentages of pamidronate disodium-treated patients compared with those in the placebo group. The reported frequencies of hypocalcemia, hypokalemia, hypophosphatemia, and hypomagnesemia for pamidronate disodium-treated patients were 3.3%, 10.5%, 1.7%, and 4.4%, respectively, and for placebo-treated patients were 1.2%, 12%, 1.7%, and 4.5%, respectively. In previous hypercalcemia of malignancy trials, patients treated with pamidronate disodium (60 or 90 mg over 24 hours) developed electrolyte abnormalities more frequently (see ADVERSE REACTIONS , Hypercalcemia of Malignancy ). Arthralgias and myalgias were reported slightly more frequently in the pamidronate disodium group than in the placebo group (13.6% and 26% vs 10.8% and 20.1%, respectively). In multiple myeloma patients, there were five pamidronate disodium-related serious and unexpected adverse experiences. Four of these were reported during the 12-month extension of the multiple myeloma trial. Three of the reports were of worsening renal function developing in patients with progressive multiple myeloma or multiple myeloma-associated amyloidosis. The fourth report was the adult respiratory distress syndrome developing in a patient recovering from pneumonia and acute gangrenous cholecystitis. One pamidronate disodium-treated patient experienced an allergic reaction characterized by swollen and itchy eyes, runny nose, and scratchy throat within 24 hours after the sixth infusion. In the breast cancer trials, there were four pamidronate disodium-related adverse experiences, all moderate in severity, that caused a patient to discontinue participation in the trial. One was due to interstitial pneumonitis, another to malaise and dyspnea. One pamidronate disodium patient discontinued the trial due to a symptomatic hypocalcemia. Another pamidronate disodium patient discontinued therapy due to severe bone pain after each infusion, which the investigator felt was trial-drug-related. Renal Toxicity In a study of the safety and efficacy of pamidronate disodium injection 90 mg (2 hour infusion) versus zoledronic acid injection 4 mg (15 minute infusion) in bone metastases patients with multiple myeloma or breast cancer, renal deterioration was defined as an increase in serum creatinine of 0.5 mg/dL for patients with normal baseline creatinine (<1.4 mg/dL) or an increase of 1 mg/dL for patients with an abnormal baseline creatinine (≥ 1.4 mg/dL). The following are data on the incidence of renal deterioration in patients in this trial. See Table 8 below. Table 8 Incidence of Renal Function Deterioration in Multiple Myeloma and Breast Cancer Patients with Normal and Abnormal Serum Creatinine at Baseline* Patient Population/ Baseline Creatinine Pamidronate Disodium Injection 90 mg/2 hours Zoledronic Acid Injection 4 mg/15 minutes n/N (%) n/N (%) Normal 20/246 (8.1%) 23/246 (9.3%) Abnormal 2/22 (9.1%) 1/26 (3.8%) Total 22/268 (8.2%) 24/272 (8.8%) * Patients were randomized following the 15 minute infusion amendment for the zoledronic acid injection arm.

Post-Marketing Experience The following adverse reactions have been reported in post-marketing use: General : reactivation of Herpes simplex and Herpes zoster, influenza-like symptoms; CNS : confusion and visual hallucinations, sometimes in the presence of electrolyte imbalance; Skin : rash, pruritus; Special senses : conjunctivitis, orbital inflammation; Renal : focal segmental glomerulosclerosis including the collapsing variant, nephrotic syndrome; Laboratory abnormalities : hyperkalemia, hypernatremia, hematuria. Rare instances of allergic manifestations have been reported, including hypotension, dyspnea, or angioedema, and, very rarely, anaphylactic shock. Pamidronate disodium is contraindicated in patients with clinically significant hypersensitivity to pamidronate disodium or other bisphosphonates (see CONTRAINDICATIONS ). Cases of osteonecrosis (primarily involving the jaw) have been reported predominantly in cancer patients treated with intravenous bisphosphonates, including pamidronate disodium. Many of these patients were also receiving chemotherapy and corticosteroids which may be risk factors for ONJ. Data suggest a greater frequency of reports of ONJ in certain cancers, such as advanced breast cancer and multiple myeloma. The majority of the reported cases are in cancer patients following invasive dental procedures, such as tooth extraction. It is therefore prudent to avoid invasive dental procedures as recovery may be prolonged (see PRECAUTIONS ).

<table> <tbody> <tr> <td rowspan="1" styleCode="Lrule Rrule Toprule Botrule" valign="top"> <paragraph> </paragraph> </td> <td colspan="5" align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>Percent of Patients</paragraph> </td> </tr> <tr> <td rowspan="2" styleCode="Lrule Rrule Toprule Botrule" valign="top"> <paragraph> </paragraph> </td> <td colspan="3" align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>Pamidronate Disodium</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>Etidronate</paragraph> <paragraph>Disodium</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>Saline</paragraph> </td> </tr> <tr> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>60 mg </paragraph> <paragraph> <content styleCode="underline">over</content> <content styleCode="underline"> 4 hr</content> </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>60 mg </paragraph> <paragraph> <content styleCode="underline">over</content> <content styleCode="underline"> 24 hr</content> </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>90 mg </paragraph> <paragraph> <content styleCode="underline">over</content> <content styleCode="underline"> 24 hr</content> </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>7.5 mg/kg </paragraph> <paragraph> <content styleCode="underline">x</content> <content styleCode="underline"> 3 days</content> </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph> </paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule" valign="top"> <paragraph> </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>n=23</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>n=73</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>n=17</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>n=35</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>n=23</paragraph> </td> </tr> <tr> <td colspan="6" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph> <content styleCode="bold">General </content> </paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Edema </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>1</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Fatigue </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>12</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule" valign="top"> <paragraph>Fever </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>26</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>19</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>18</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>9</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Fluid overload </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>6</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Infusion-site reaction </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>4</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>18</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Moniliasis </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>6</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule" valign="top"> <paragraph>Rigors </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>4</paragraph> </td> </tr> <tr> <td colspan="6" styleCode="Lrule Rrule Toprule Botrule"> <paragraph> <content styleCode="bold">Gastrointestinal </content> </paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Abdominal pain </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>1</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule" valign="top"> <paragraph>Anorexia </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>4</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>1</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>12</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Constipation </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>4</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>6</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>3</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule" valign="top"> <paragraph>Diarrhea </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>1</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Dyspepsia </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>4</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Gastrointestinal hemorrhage </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>6</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule" valign="top"> <paragraph>Nausea </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>4</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>18</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>6</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Stomatitis </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>1</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>3</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule" valign="top"> <paragraph>Vomiting </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>4</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> </tr> <tr> <td colspan="6" styleCode="Lrule Rrule Toprule Botrule"> <paragraph> <content styleCode="bold">Respiratory </content> </paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule" valign="top"> <paragraph>Dyspnea </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>3</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule" valign="top"> <paragraph>Rales </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>6</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Rhinitis </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>6</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule" valign="top"> <paragraph>Upper respiratory infection </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>3</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> </tr> <tr> <td colspan="6" styleCode="Lrule Rrule Toprule Botrule"> <paragraph> <content styleCode="bold">CNS </content> </paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Anxiety </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>4</paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule" valign="top"> <paragraph>Convulsions </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>3</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Insomnia </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>1</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Nervousness </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>4</paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Psychosis </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>4</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule" valign="top"> <paragraph>Somnolence </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>1</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>6</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule" valign="top"> <paragraph>Taste perversion </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>3</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> </tr> <tr> <td colspan="6" styleCode="Lrule Rrule Toprule Botrule"> <paragraph> <content styleCode="bold">Cardiovascular </content> </paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Atrial fibrillation </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>6</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>4</paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Atrial flutter </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>1</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Cardiac failure </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>1</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Hypertension </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>6</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>4</paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule" valign="top"> <paragraph>Syncope </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>6</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule" valign="top"> <paragraph>Tachycardia </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>6</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>4</paragraph> </td> </tr> <tr> <td colspan="6" styleCode="Lrule Rrule Toprule Botrule"> <content styleCode="bold">Endocrine </content> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule" valign="top"> <paragraph>Hypothyroidism </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>6</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> </tr> <tr> <td colspan="6" styleCode="Lrule Rrule Toprule Botrule"> <paragraph> <content styleCode="bold">Hemic and Lymphatic </content> </paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule" valign="top"> <paragraph>Anemia </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>6</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Leukopenia </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>4</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule" valign="top"> <paragraph>Neutropenia </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>1</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule" valign="top"> <paragraph>Thrombocytopenia </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>1</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> </tr> <tr> <td colspan="6" styleCode="Lrule Rrule Toprule Botrule"> <content styleCode="bold">Musculoskeletal</content> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule" valign="top"> <paragraph>Myalgia </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>1</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> </tr> <tr> <td colspan="6" styleCode="Lrule Rrule Toprule Botrule"> <paragraph> <content styleCode="bold">Urogenital</content> </paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule" valign="top"> <paragraph>Uremia </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>4</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> </tr> <tr> <td colspan="6" styleCode="Lrule Rrule Toprule Botrule" valign="top"> <paragraph> <content styleCode="bold">Laboratory Abnormalities </content> </paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Hypocalcemia </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>1</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>12</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule" valign="top"> <paragraph>Hypokalemia </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>4</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>4</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>18</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule" valign="top"> <paragraph>Hypomagnesemia </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>4</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>10</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>12</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>3</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>4</paragraph> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule Botrule" valign="top"> <paragraph>Hypophosphatemia </paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>9</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>18</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>3</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> </tr> <tr> <td rowspan="1" styleCode="Lrule Rrule Toprule Botrule" valign="top"> <paragraph>Abnormal liver function</paragraph> </td> <td rowspan="1" align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td rowspan="1" align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td rowspan="1" align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> <td rowspan="1" align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>3</paragraph> </td> <td rowspan="1" align="center" styleCode="Lrule Rrule Toprule Botrule" valign="bottom"> <paragraph>0</paragraph> </td> </tr> </tbody> </table>